Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.
Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.
复制标题
使用纳米粒子进行原位癌症疫苗接种：机制和免疫疗法的好处。
DOI：
10.1080/02656736.2020.1802519
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Ranjan A
中科院分区：
文献类型：
--
作者：
Gorbet MJ;Singh A;Mao C;Fiering S;Ranjan A
治疗癌症的免疫疗法现在是一种成熟的临床方法。免疫治疗可以全身应用，如检查点阻断抗体，但也可以直接注射到已确定的肿瘤中，采用原位疫苗接种（ISV）策略。ISV旨在刺激涉及先天性和适应性免疫细胞的强烈局部抗肿瘤免疫应答，并通过此产生针对转移性肿瘤的全身抗肿瘤免疫应答。已经利用多种ISV来产生免疫刺激性肿瘤微环境（TME）。这些包括减毒微生物、重组蛋白、小分子、TME的物理干扰物（交变磁和聚焦超声加热、光热疗法和放射疗法）以及最近的纳米颗粒（NP）。纳米颗粒是有吸引力的和独特的，因为它们可以负载多种药物或其他试剂以影响TME中的免疫和癌细胞功能，从而提供刺激抗肿瘤免疫的独特机会。在此，我们描述了NP-ISV的治疗机制，综述了化学合成的NPs（即脂质体、聚合物、壳聚糖基、无机NPs等），生物衍生的NP（基于病毒和细菌的NP），以及能量激活的NP-ISV（在它们用作本地ISV的情况下）。数据表明，NP-ISV可以增强免疫治疗方案的结果，包括那些利用肿瘤热疗和检查点阻断疗法的免疫治疗方案。
Immunotherapy to treat cancer is now an established clinical approach. Immunotherapy can be applied systemically, as done with checkpoint blockade antibodies, but it can also be injected directly into identified tumors, in a strategy of in situ vaccination (ISV). ISV is designed to stimulate a strong local antitumor immune response involving both innate and adaptive immune cells, and through this generate a systemic antitumor immune response against metastatic tumors. A variety of ISVs have been utilized to generate an immunostimulatory tumor microenvironment (TME). These include attenuated microorganisms, recombinant proteins, small molecules, physical disruptors of TME (alternating magnetic and focused ultrasound heating, photothermal therapy and radiotherapy), and more recently nanoparticles (NPs). NPs are attractive and unique since they can load multiple drugs or other reagents to influence immune and cancer cell functions in the TME, affording a unique opportunity to stimulate antitumor immunity. Here, we describe the NP-ISV therapeutic mechanisms, review chemically synthesized NPs (i.e. liposomes, polymeric, chitosan based, inorganic NPs, etc.), biologically derived NPs (virus and bacteria based NPs), and energy activated NP-ISVs in the context of their use as local ISV. Data suggests that NP-ISVs can enhance outcomes of immunotherapeutic regimens including those utilizing tumor hyperthermia and checkpoint blockade therapies.
登录
查看更多内容
影响因子：
16.6
作者：
通讯作者：
--
影响因子：
5.4
作者：
Cano-Mejia, Juliana;Burga, Rachel A.;Sweeney, Elizabeth E.;Fisher, John P.;Bollard, Catherine M.;Sandler, Anthony D.;Cruz, Conrad Russell Y.;Fernandes, Rohan
通讯作者：
Fernandes, Rohan
DOI：
10.1007/s11693-010-9066-z
发表时间：
2011-06-01
期刊：
Systems and synthetic biology
影响因子：
--
作者：
Amidi, Maryam;de Raad, Markus;Mastrobattista, Enrico
通讯作者：
Mastrobattista, Enrico
影响因子：
3.1
作者：
Duval, Kayla E. A.;Vernice, Nicholas A.;Hoopes, P. Jack
通讯作者：
Hoopes, P. Jack
影响因子：
18.2
作者：
Cha BG;Jeong JH;Kim J
通讯作者：
Kim J